Your browser doesn't support javascript.
Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination.
Nogimori, Takuto; Suzuki, Koichiro; Masuta, Yuji; Washizaki, Ayaka; Yagoto, Mika; Ikeda, Mami; Katayama, Yuki; Kanda, Hidenori; Takada, Minoru; Minami, Shohei; Kobayashi, Takeshi; Takahama, Shokichi; Yoshioka, Yasuo; Yamamoto, Takuya.
  • Nogimori T; Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • Suzuki K; Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Masuta Y; The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Osaka, Japan.
  • Washizaki A; Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • Yagoto M; Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
  • Ikeda M; Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • Katayama Y; Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Kanda H; Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • Takada M; Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • Minami S; Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • Kobayashi T; KINSHUKAI, Hanwa Memorial Hospital, Osaka, Japan.
  • Takahama S; KINSHUKAI, Hanwa The Second Senboku Hospital, Osaka, Japan.
  • Yoshioka Y; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Yamamoto T; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Front Immunol ; 13: 1081047, 2022.
Article in English | MEDLINE | ID: covidwho-2233832
ABSTRACT
Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8+ T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8+ T cells cross-reacting to BA.1, whereas the T-cell receptor (TCR) repertoire usages decreased with time. Furthermore the mRNA vaccine induced spike-specific CD8+ T cells subpopulation expressing Granzyme A (GZMA), Granzyme B (GZMB) and Perforin simultaneously in healthy donors at 4 weeks after the second vaccination. The induced subpopulation was not maintained at 12 weeks after the second vaccination. Incorporating factors that efficiently induce CD8+ T cells with highly cytotoxic activity could improve future vaccine efficacy against such variants.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antineoplastic Agents Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1081047

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antineoplastic Agents Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1081047